Does Moderna's Cancer Breakthrough Make It a Good Stock to Buy Now?
Personalization is all the rage these days. Whether we're talking about the business of entertainment, food, or clothing, consumers have more options today than anyone imagined possible a couple of decades ago.
Moderna (NASDAQ: MRNA) and its big pharma collaboration partner, Merck (NYSE: MRK), recently posted compelling clinical-trial results that suggest cancer treatments are about to become a lot more personalized too. On Monday, June 5, the partners showed off compelling results for a personalized cancer vaccine that Moderna calls mRNA-4157 and Merck calls V940.
There are a whole lot of ins and outs when it comes to interpreting cancer-trial data. Let's look at the most important details to see if Moderna's a smart stock to buy now.
A big improvement
Keytruda is a popular immunotherapy from Merck that takes the brakes off the immune system so it can fight tumors. It's highly effective for some patients, but it doesn't seem to accomplish anything for most who receive it. Merck and companies with similar drugs have been hard at work for years trying to make Keytruda and other drugs like it effective for more people.